Open-Label, Non-Randomized, Non-Controlled, Multicenter Phase II Study Investigating Cetuximab in Combination With Concomitant-Boost Radiotherapy as First-Line Treatment for Japanese Patients With Newly Diagnosed Locally Advanced SCCHN.
Phase of Trial: Phase II
Latest Information Update: 07 May 2014
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 17 Aug 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.